

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): August 6, 2014

**RELMADA THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

---

**Nevada**

(State or other jurisdiction of  
incorporation)

---

**333-184881**

(Commission File Number)

---

**45-5401931**

(IRS Employer  
Identification No.)

---

**546 Fifth Avenue, 14<sup>th</sup> Floor**  
**New York, NY**

(Address of principal executive offices)

---

**10036**

(Zip Code)

Registrant's telephone number, including area code **(212) 702-7163**

---

**Camp Nine, Inc.**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 7.01. Regulation FD Disclosure.**

On July 8, 2014, Relmada Therapeutics, Inc. (the "Company") changed its name from Camp Nine, Inc. to Relmada Therapeutics, Inc (the "Name Change"). This became effective in accordance with Certificate of Amendment to Articles of Incorporation filed with the State of Nevada. In connection with the Financial Industry Regulatory Authority's ("FINRA") Rule 6490 and Rule 10b-17 of the United States Securities Exchange Act of 1934, as amended, on July 9, 2014, the Company submitted an issuer company-related action notification form to FINRA notifying FINRA of the Name Change. On August 5, 2014, FINRA notified the Registrant that the Name Change had been approved with an effective date of August 6, 2014.

On August 6, 2014, in connection with the Name Change, the Company issued the press release attached hereto as Exhibit 99.1 announcing the Name Change. In accordance with General Instruction B.2 of Form 8-K, the information set forth herein and in the press release is deemed to be "furnished" and shall not be deemed to be "filed" for purposes of the Securities Exchange Act of 1934, as amended. The information set forth in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

**Item 8.01 Other Events**

In connection with the Name Change, the Company also requested and received an updated stock trading ticker symbol, "RLMD", which was assigned and deemed effective by FINRA as of August 6, 2014, with respect to the Company's shares of common stock. In addition, as a result of the Name Change, the Company's new CUSIP number is " 75955J105".

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release, dated August 6, 2014.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 7, 2014

**RELMADA THERAPEUTICS, INC.**

By: /s/ Sergio Traversa  
Name: Sergio Traversa  
Title: Chief Executive Officer

# Relmada Therapeutics, Inc. Completes Name Change and Announces New Ticker

*The Company's New Ticker Is RLMD*

**New York, NY August 6, 2014** – Relmada Therapeutics, Inc., (OTCBB: RLMD), a Nevada corporation (the “Company”), a clinical-stage company developing novel therapies for the treatment of chronic pain is pleased to announce that Financial Industry Regulatory Authority (FINRA) has approved the Company's application for a name change from Camp Nine, Inc. to Relmada Therapeutics, Inc. and assigned a new trading symbol, RLMD.

The Company also received a new CUSIP number, 75955J105 for its common stock. This change was made in conjunction with the Company's filing of a Certificate of Amendment to its Articles of Incorporation, on July 8, 2014, changing the Company's name from Camp Nine, Inc. to Relmada Therapeutics, Inc. The former ticker symbol of the Company was CMPE. The effective date for these changes is today August 6, 2014.

“Management is extremely pleased to announce our new name and trading symbol,” said Sergio Traversa, CEO of Relmada Therapeutics Inc. “We are confident that this will help the investors to better identify us with our strategic focus, which is to serve as a market leader in the successful development of new chemical entities that address the treatment of pain. With the public listing process now complete, the Company can now focus its efforts on the development, advancement and commercialization of our four programs in various stages of clinical trials.”

Relmada is currently developing LevoCap ER, its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for neuropathic pain; BuTab ER, its oral dosage form of the opioid analgesic buprenorphine and MepiGel, its FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine.

## **About Relmada Therapeutics Inc.**

Relmada Therapeutics is a clinical stage, public specialty pharmaceutical company, focused on developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at different stages of development and a deep early stage pipeline. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team with inputs from a world-class scientific advisory board. The Company's approach is expected to reduce overall clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.

---

## **Forward-Looking Statements**

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected.

Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Visit our website at, [www.relmada.com](http://www.relmada.com)

## **Contact**

Sergio Traversa, CEO  
Relmada Therapeutics Inc.  
Tel: 646-801-8112  
[straversa@relmada.com](mailto:straversa@relmada.com)

## **Media contact:**

Janet Vasquez  
JV Public Relations NY  
Tel: 212-645-5498  
[jvasquez@jvprny.com](mailto:jvasquez@jvprny.com)